Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)

Figures & data

Table 1 Baseline Demography And Clinical Characteristics

	All Patients (n=119)	Lanreotide-Treated (n=53)	Octreotide-Treated (n=66)
Sex
Male	72 (60.5)	26 (49.1)	46 (69.7)
Female	47 (39.5)	27 (50.9)	20 (30.3)
Age, mean (SD)	63.9 (10.2)	64.0 (11.2)	63.8 (9.5)
Primary tumor localization
Small intestine	88 (73.9)	34 (64.2)	54 (81.8)
Pancreas	16 (13.4)	11 (20.8)	5 (7.6)
Other	10 (8.4)	4 (7.5)	6 (9.1)
Unknown	5 (4.2)	4 (7.5)	1 (1.5)
Surgery of primary tumor	91 (77.1)	43 (82.7)	48 (72.7)
Tumor grade
G1	66 (55)	32 (61)	32 (49)
G2	53 (45)	21 (39)	34 (51)
Chromogranin A test
No	1 (0.8)	1 (1.9)	0 (0.0)
Yes:	118 (99.2)	52 (98.1)	66 (100.0)
% ULN, ref <2.0 nmol/L	10 (8.5)	4 (7.7)	6 (9.1)
% ULN, ref <3.0 nmol/L	31 (26.3)	17 (32.7)	14 (21.2)
5-HIAA test
Yes	101 (84.9)	41 (77.4)	60 (90.9)
No	18 (15.1)	12 (22.6)	6 (9.1)
Comorbidity
Any	63 (52.9)	33 (62.3)	30 (45.5)
Cardiovascular disease	57 (47.9)	27 (50.9)	30 (45.5)
Diabetes	13 (10.9)	9 (17.0)	4 (6.1)
Other tumor disease	9 (7.6)	6 (11.5)	3 (4.5)
Smoker
Yes	9 (7.6)	3 (5.7)	6 (9.14)
Married/living with a partner
Yes	92 (78.0)	42 (79.2)	50 (76.9)
Education level
Elementary school	35 (30.4)	13 (25.0)	22 (34.9)
High school	28 (24.3)	13 (25.0)	15 (23.8)
Post high school	52 (45.2)	26 (50.1)	26 (41.3)

Note: All values are n (%) unless otherwise stated.

Abbreviations: 5-HIAA, 5-Hydroxyindoleacetic acid; G1, Grade 1; G2, Grade 2; ref, reference; ULN, upper limit of normal.

Figure 1 Patient anxiety levels before injection with lanreotide and octreotide. Answer to question: To what extent do you feel anxiety before the injection?

Table 2 SF-12 Mean Physical And Mental Composite Scores (Levene's Test for Equality of Variances)

	Physical Composite Score	95% CI Of Difference^a	P-value	Mental Composite Score	P-value	95% CI Of Difference^a
Overall population (n=110)	38.4		–	50.1	-
SSA treatment  Lanreotide (n=47)  Octreotide (n=63)	39.4 37.6	−1.02; 4.56	0.211	50.7 49.6	0.626	−3.30; 5.46
Sex  Male (n=66)  Female (n=44)	38.8 37.9	−3.77; 2.02	0.548	52.4 46.6	0.009	−10.20; −1.48
Age  <65 years (n=46)  ≥65 years (n=64)	37.6 39.0	−4.32; 1.49	0.335	47.2 52.2	0.022	−9.30; −0.73

Notes: ^a95% CI of difference between lanreotide and octreotide. Scores can range from 0 to 100, where higher scores = better HRQoL

Abbreviations: CI, confidence interval; HRQoL, health-related quality of life; SF-12, Short Form-12; SSA, somatostatin analogue.

Figure 2 Patient awareness about the possibility of SSA self-injection. Answer to question: If not self-injecting, has the hospital staff informed you about the possibility to self-inject?

Abbreviations: SSA, somatostatin analogues.